BidaskClub cut shares of Corium International (NASDAQ:CORI) from a sell rating to a strong sell rating in a research report released on Saturday morning.
CORI has been the subject of several other reports. Zacks Investment Research upgraded Corium International from a sell rating to a hold rating in a research report on Tuesday, August 14th. ValuEngine upgraded Corium International from a hold rating to a buy rating in a research report on Friday, August 10th. Cantor Fitzgerald restated a buy rating and set a $14.00 price objective on shares of Corium International in a research report on Friday, August 10th. Finally, HC Wainwright restated a buy rating and set a $13.00 price objective on shares of Corium International in a research report on Monday, August 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Corium International has a consensus rating of Buy and an average target price of $12.80.
Shares of Corium International stock opened at $9.45 on Friday. The company has a current ratio of 7.61, a quick ratio of 7.47 and a debt-to-equity ratio of 2.83. Corium International has a 1 year low of $7.17 and a 1 year high of $13.93.
In other Corium International news, insider Joseph J. Sarret sold 3,565 shares of the business’s stock in a transaction on Friday, August 17th. The stock was sold at an average price of $9.01, for a total value of $32,120.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Peter D. Staple sold 76,341 shares of the business’s stock in a transaction on Friday, August 17th. The shares were sold at an average price of $8.81, for a total value of $672,564.21. Following the completion of the transaction, the chief executive officer now owns 362,316 shares of the company’s stock, valued at $3,192,003.96. The disclosure for this sale can be found here. Insiders have sold a total of 119,965 shares of company stock valued at $1,060,275 over the last 90 days. Insiders own 30.80% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of CORI. DekaBank Deutsche Girozentrale acquired a new position in Corium International in the 1st quarter valued at $167,000. Engineers Gate Manager LP acquired a new position in Corium International in the 2nd quarter valued at $215,000. Alps Advisors Inc. acquired a new position in Corium International in the 2nd quarter valued at $420,000. Citadel Advisors LLC acquired a new position in Corium International in the 1st quarter valued at $455,000. Finally, Schwab Charles Investment Management Inc. raised its holdings in Corium International by 40.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 58,309 shares of the biopharmaceutical company’s stock valued at $468,000 after acquiring an additional 16,900 shares during the last quarter.
Corium International Company Profile
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Recommended Story: Market Capitalization
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.